Renowned Harvard-trained American cancer surgeon talks about his optimism in more breakthroughs in metastatic peritoneal cancer treatment in the future. How a small group of pioneering cancer surgeons developed metastatic cancer treatment procedure. It is now used by thousands of surgeons around the world. What are challenges in cancer treatment in the Middle East, South America and Asia? Dr. Paul Sugarbaker leads international cancer surgeons. Metastatic peritoneal cancer treatment future. Dr. Anton Titov, MD. Leading peritoneal metastatic cancer from colon cancer, ovarian cancer, gastric cancer, appendiceal cancer speaks of future advances in treatment of peritoneal metastases. Dr. Paul Sugarbaker, MD. The chemotherapy that goes with a cytoreductive surgery to treat metastatic peritoneal cancer must be optimized. Dr. Anton Titov, MD. Surgeons must perform a cytoreductive surgery that is down to the microscopic level of cancer metastatic disease. Huge challenge with quality of cancer surgery in developing countries: Middle East, Egypt, Saudi Arabia, United Arab Emirates, Russia, South America, Brazil, Chili, Argentina, Mexico. Colon cancer, gastric cancer, ovarian cancer spread in the abdomen and peritoneal cavity. Peritoneal metastases in advanced stage 4 colon cancer treatment by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) [hot chemo bath, heated chemotherapy]. Medical second opinion clarifies colon cancer or ovarian cancer diagnosis. Medical second opinion confirms that cure is possible in metastatic colon cancer. Intraperitoneal chemotherapy treatment for advanced stage 4 cancer with metastatic lesions in the abdomen. Dr. Paul Sugarbaker, MD. Medical second opinion helps to select a precision medicine treatment for stage 4 ovarian cancer or stage 4 colon cancer or metastatic stage 4 gastric cancer. Get medical second opinion on advanced cancer with peritoneal metastases. Dr. Anton Titov, MD. Best peritoneal metastatic advanced cancer treatment by surgical operation and regional chemotherapy. Video interview with Dr. Paul Sugarbaker. Leading expert in peritoneal metastatic cancer treatment (cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC), hot chemo bath, heated chemotherapy. Metastatic peritoneal cancer treatment future. Cytoreductive surgery quality for peritoneal cancer treatment. Dr. Anton Titov, MD. Dr. Sugarbaker, you pioneered and together with your colleagues developed the peritoneal metastatic cancer treatment procedure. It is now known as the Sugarbaker Procedure. Sugarbaker Procedure is a cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Dr. Anton Titov, MD. Where do you see this peritoneal metastatic cancer treatment method going into the future? How do you see the Sugarbaker procedure developing in the next several years? You are working hard to bring cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to more peritoneal metastatic cancer patients. Dr. Anton Titov, MD. What is the future for peritoneal metastatic cancer treatment? (peritoneal metastases from colon cancer, ovarian cancer, gastric cancer) Dr. Paul Sugarbaker, MD. Renowned Gastrointestinal Cancer Surgeon. The future for peritoneal metastatic cancer treatment is limitless. 20 years ago we had the first international congress on peritoneal surface oncology. It was in London at a small hospital, North Hampshire hospital. Dr. Paul Sugarbaker, MD. There were about 30 or 40 people at that first peritoneal cancer treatment symposium. I had no idea that time that peritoneal metastatic cancer treatment would be growing the method that it is now. next year in Washington, DC we will get together with about a 1,000 surgeons and oncologists from around the world to discuss best peritoneal metastatic cancer treatment. Dr. Paul Sugarbaker, MD. Renowned Gastrointestinal Cancer Surgeon. We will try and think through now, 20 years later, where are we going with the treatment of peritoneal metastases. Dr. Paul Sugarbaker, MD. We have not found out the optimal medications to use on individual patients with peritoneal cancer metastatic disease (from colon cancer, ovarian cancer, gastric cancer). We need to optimize the chemotherapy that goes with a cytoreductive surgery. Dr. Anton Titov, MD. This is a good word, " optimize". But there is a huge challenge in terms of surgical technology education about cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). I would say that are our greatest challenge at this point in time is to educate surgeons to perform a cytoreductive surgery that is down to the microscopic level of cancer metastatic disease. Surgeons have to do cytoreductive surgery with a less than 1% mortality and with less than 10% serious complication rate. That is the number one focus of our activity at this point in time on quality of cytoreductive surgery in peritoneal metastatic cancer. Dr. Paul Sugarbaker, MD. We will be working on educating cancer surgeons on reducing death rate and complications rate at this congress with videos and workshops. Videos and workshops allow knowledge of best practices in peritoneal metastatic cancer treatment to be safely disseminated around the globe. Dr. Paul Sugarbaker, MD. Renowned Gastrointestinal Cancer Surgeon. High quality of cytoreductive surgery is a challenge in the United States, Europe, Japan and Korea. But what about the developing countries? Well, there is a huge challenge with quality of cancer surgery in developing countries? What about cancer surgery quality with our islamic neighbors? We are trying to get peritoneal cancer surgery education efforts going now in Kuwait and Saudi Arabia. We have got a peritoneal cancer surgery conference coming up in Cairo, Egypt. But it is a huge challenge there. Because the level of surgical expertise is not the same as we have in the US. You know, I was trained at Harvard. Then at National Institute of Health. Dr. Paul Sugarbaker, MD. Renowned Gastrointestinal Cancer Surgeon. I had absolutely the best training in surgery you could ever imagine. We don't have that quality of surgical training around the world. South America is a huge challenge in quality cancer surgery training. Dr. Paul Sugarbaker, MD. We have made some real progress in Mexico, with a big effort to educate cancer surgeons. But is cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) a treatment only for the United States and Europe? it is not. Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a treatment that should be initiated around the globe. Dr. Anton Titov, MD. That is a huge challenge. Metastatic peritoneal cancer treatment future: It is limitless. Leading cancer surgeon discusses advances in metastatic abdominal stage 4 cancer therapy.